The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC).
Maria Catherine Pietanza
Research Funding - Novartis
Lee M. Krug
No relevant relationships to disclose
Anna M. Varghese
No relevant relationships to disclose
Martin Fleisher
No relevant relationships to disclose
Jerrold B. Teitcher
No relevant relationships to disclose
Andrei Holodny
No relevant relationships to disclose
Camelia S. Sima
No relevant relationships to disclose
Anna Maria Litvak
No relevant relationships to disclose
Kenneth K. Ng
No relevant relationships to disclose
Payal R. Patel
No relevant relationships to disclose
Fawzia Ibrahim
No relevant relationships to disclose
Anne Haughney-Siller
No relevant relationships to disclose
Dorothy Dulko
No relevant relationships to disclose
Grace Monger
No relevant relationships to disclose
Melanie Albano
No relevant relationships to disclose
Clare M Moran
No relevant relationships to disclose
Mark G. Kris
Consultant or Advisory Role - Novartis
Charles M. Rudin
Consultant or Advisory Role - AVEO; Celgene; Merck